Sapanisertib is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays.

Taselisib is an orally bioavailable inhibitor of the class I phosphatidylinositol 3-kinase (PI3K) alpha isoform (PIK3CA), with potential antineoplastic activity.

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3.

OSI-027 is an orally bioavailable mammalian target of rapamycin (mTOR) kinase inhibitor with potential antineoplastic activity.

AS-604850 is a potent, selective and ATP-competitive PI3Kγ inhibitor with an IC50 value of 0.25 μM and a Ki value of 0.18 μM. AS-604850 is isoformselective inhibitor of PI3Kγ with over 30-fold selectivity for PI3Kδ and β, and 18-fold selectivity over PI3Kα, respectively.

ZSTK474 inhibits class I PI3K isoforms with IC50 of 37 nM in a cell-free assay, mostly PI3Kδ. Phase1/2.

6-amino-4-methoxy analogue of ZSTK474 inhibits PI3K isoforms with IC50 of 0.22nm, 1.4nm and 0.38nm for p110α, p110β and p110δ, respectively.

It is an analogue of ZSTK474.